Research Networks
WIRE investigators work through 5 multicenter research networks that link multiple partner institutions in the United States, Canada, and Europe. Shared sites, shared investigators, and shared infrastructure let each study build on the last.
Atlas
- Partner institutions
- 47
- Countries
- 3
- Research networks
- 5
- Shared sites
- 23
Hover or tap a site for detailsScroll sideways for Europe →
5 networks
Where WIRE works
WIRE investigators take part in multicenter research networks that share sites, investigators, and infrastructure. Select a network to trace its sites from Milwaukee.
Legend
- WIRE at the Medical College of Wisconsin
- Partner site
- One ring per network with a site in that city
Highlights the location on the map
The networks
Networks & consortia
01
RESUME Trial NetworkWIRE-led · 26 sites · Under review at NHLBI and CIHR
WIRE-led · Clinical Coordinating Center & single IRB
Under review at NHLBI and CIHR
- Principal investigator
- Zachary Smith, DO, MSc
- Funding
- Submitted to NHLBI (UG3/UH3 Clinical Coordinating Center and companion U24 Data Coordinating Center) and to CIHR; under review at both
The RESUME trial network will conduct the first randomized trial of when to resume direct oral anticoagulants (DOACs) after high-risk gastrointestinal endoscopy. The Medical College of Wisconsin serves as the Clinical Coordinating Center and single IRB, with the Northwestern University Data Analysis and Coordinating Center as the Data Coordinating Center and the TIMI Study Group providing blinded central adjudication of bleeding and thromboembolic events. The network builds on the site infrastructure of the multicenter Stent versus Indomethacin (SVI) trial.
Aim
Determine whether delaying DOAC resumption after high-risk endoscopy reduces 30-day clinically significant GI bleeding without a clinically meaningful increase in 90-day ischemic stroke or systemic embolism.
Sites · 26
- Medical College of WisconsinMilwaukee, WI
- AdventHealth OrlandoOrlando, FL
- Atrium Health Wake Forest BaptistWinston-Salem, NC
- Aurora St. Luke's Medical CenterMilwaukee, WI
- Baylor Scott & White Research InstituteDallas, TX
- Brigham and Women's HospitalBoston, MA
- Cedars-Sinai Medical CenterLos Angeles, CA
- Dartmouth-Hitchcock Medical CenterLebanon, NH
- Emory UniversityAtlanta, GA
- Henry Ford HealthDetroit, MI
- Massachusetts General HospitalBoston, MA
- Mayo ClinicRochester, MN
- Northwestern UniversityChicago, IL
- Oregon Health & Science UniversityPortland, OR
- The Ohio State University Wexner Medical CenterColumbus, OH
- UCLALos Angeles, CA
- University Hospitals Cleveland Medical CenterCleveland, OH
- University of CalgaryCalgary, AB
- University of Colorado Anschutz Medical CampusAurora, CO
- University of Kansas Medical CenterKansas City, KS
- University of Oxford Clinical Trial Service UnitOxford, United Kingdom
- University of PittsburghPittsburgh, PA
- University of Southern CaliforniaLos Angeles, CA
- University of VirginiaCharlottesville, VA
- UT Southwestern Medical CenterDallas, TX
- Washington University in St. LouisSt. Louis, MO
02Stents Versus Indomethacin (SVI) NetworkWIRE participating site · 23 sites · Trial completed
Participating site
Trial completed
- Principal investigator
- B. Joseph Elmunzer, MD, MSc (Medical University of South Carolina)
- Funding
- National Institutes of Health (NIDDK), grant U01DK104833
The Stents Versus Indomethacin (SVI) trial was a landmark, multicenter, randomized, double-blind, non-inferiority trial evaluating whether rectal indomethacin alone is as effective as the combination of rectal indomethacin plus prophylactic pancreatic stent placement for preventing pancreatitis after high-risk ERCP. The trial established that indomethacin alone was not as effective as the combined strategy, supporting current guideline recommendations to use both interventions in high-risk cases. The SVI Study Group continues to collaborate on impactful research, including post hoc SVI analyses and other impactful endoscopic research.
Aim
To determine whether prophylactic pancreatic stent placement provides additional benefit over rectal indomethacin alone in preventing post-ERCP pancreatitis among high-risk patients.
Sites · 23
- Medical College of WisconsinMilwaukee, WI
- Brigham and Women's HospitalBoston, MA
- Dartmouth-Hitchcock Medical CenterLebanon, NH
- Emory UniversityAtlanta, GA
- Johns Hopkins MedicineBaltimore, MD
- Mayo ClinicRochester, MN
- McGill University Health CentreMontreal, QC
- Medical University of South CarolinaCharleston, SC
- Northwestern UniversityChicago, IL
- Oregon Health & Science UniversityPortland, OR
- Orlando Health Digestive Health InstituteOrlando, FL
- The Ohio State University Wexner Medical CenterColumbus, OH
- University Hospitals Cleveland Medical CenterCleveland, OH
- University of CalgaryCalgary, AB
- University of Colorado Anschutz Medical CampusAurora, CO
- University of Kansas Medical CenterKansas City, KS
- University of MichiganAnn Arbor, MI
- University of PittsburghPittsburgh, PA
- University of Southern CaliforniaLos Angeles, CA
- University of VirginiaCharlottesville, VA
- Vanderbilt University Medical CenterNashville, TN
- Virginia Mason Medical CenterSeattle, WA
- Washington University in St. LouisSt. Louis, MO
03Large Polyp Study (LPS) GroupWIRE participating site · 18 sites
Participating site
- Principal investigator
- Heiko Pohl, MD
- Funding
- Supported by research grants from STERIS and Cosmo Pharmaceuticals
The Large Polyp Study Group is a collaborative research network conducting multiple high-impact studies on advanced endoscopic resection techniques for large colorectal polyps. Their hallmark work — a large, multicenter randomized controlled trial comparing cold snare EMR and hot EMR for large colon polyps — was ultimately published in Gut and is regarded as a major contribution to the field. The group continues to collaborate on innovative, practice-changing EMR research across diverse academic centers.
Aim
To advance the safety, efficacy, and technique of endoscopic mucosal resection (EMR) for large colorectal polyps through multicenter, collaborative research.
Sites · 18
- Medical College of WisconsinMilwaukee, WI
- AdventHealth OrlandoOrlando, FL
- Beth Israel Deaconess Medical CenterBoston, MA
- Centre hospitalier de l'Université de Montréal (CHUM)Montreal, QC
- Dartmouth-Hitchcock Medical CenterLebanon, NH
- Henry Ford HealthDetroit, MI
- Indiana University School of MedicineIndianapolis, IN
- Mayo Clinic JacksonvilleJacksonville, FL
- Medical University of South CarolinaCharleston, SC
- Northwestern UniversityChicago, IL
- NYU Langone HealthNew York, NY
- Penn State Health Milton S. Hershey Medical CenterHershey, PA
- Sanford Center for Digestive HealthSioux Falls, SD
- Spectrum Health Butterworth HospitalGrand Rapids, MI
- University of Kansas Medical CenterKansas City, KS
- University of Nebraska Medical CenterOmaha, NE
- White River Junction VA Medical CenterWhite River Junction, VT
- Yale New Haven HospitalNew Haven, CT
04
CAN Resect: The Canadian Resection Research Group (CHUM)WIRE participating site · 9 sites
Participating site
- Principal investigator
- Daniel von Renteln, MD (CHUM, Montreal)
- Funding
- Supported by the Canadian Institutes of Health Research (CIHR)
The CAN Resect Study Group is a collaborative research network uniting leading centers across the US and Canada to advance the safety and efficacy of endoscopic mucosal resection (EMR) for large colorectal polyps. The group conducts multicenter, randomized trials that address the most pressing clinical questions in polyp resection, including innovations in non-thermic techniques, prevention of recurrence, and the role of adjuvant therapies. Its studies are shaping guidelines and best practices for endoscopic management of large polyps.
Aim
To compare innovative EMR techniques — such as non-thermic EMR and adjuvant thermal ablation — for large colorectal polyps, aiming to reduce recurrence and adverse events while improving cost-effectiveness and patient safety.
Sites · 9
- Medical College of WisconsinMilwaukee, WI
- Centre hospitalier de l'Université de Montréal (CHUM)Montreal, QC
- Forzani & MacPhail Colon Cancer Screening CentreCalgary, AB
- Johns Hopkins MedicineBaltimore, MD
- London Health Sciences CentreLondon, ON
- McGill University Health CentreMontreal, QC
- St. Michael's Hospital, University of TorontoToronto, ON
- St. Paul's HospitalVancouver, BC
- White River Junction VA Medical CenterWhite River Junction, VT
05CReATE NetworkWIRE participating site · 4 sites
Participating site
- Principal investigator
- Nauzer Forbes, MD, MSc (University of Calgary)
- Funding
- Intramural
The Calgary Registry for Advanced and Therapeutic Endoscopy (CReATE) is a prospective, multi-center registry designed to capture detailed clinical, technical, and outcome data for ERCP procedures performed across leading Canadian centers. CReATE serves as a foundational data platform for high-impact studies on ERCP effectiveness, safety, risk factors for adverse events, and training outcomes, ultimately aiming to improve the quality and value of endoscopic care.
Aim
To systematically collect and analyze data on ERCP procedures in order to better understand clinical effectiveness, patient outcomes, risk factors for adverse events, and the impact of educational practices in advanced endoscopy.
Sites · 4
- Medical College of WisconsinMilwaukee, WI
- McGill University Health CentreMontreal, QC
- St. Michael's Hospital, University of TorontoToronto, ON
- University of CalgaryCalgary, AB